Sibutramine and psychosis

Journal of Clinical Psychopharmacology

Volumn 27, Issue 6, 2007, Pages 726-727

  Litvan, Lia ^a   Alcoverro Fortuny, Òscar ^a  

^a Centres Assistencials   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

RISPERIDONE; SIBUTRAMINE; ANOREXIGENIC AGENT; CYCLOBUTANE DERIVATIVE;

ADULT; BEHAVIOR DISORDER; BLOOD PRESSURE; BRIEF PSYCHIATRIC RATING SCALE; CASE REPORT; DELUSION; DRUG DOSE INCREASE; FEMALE; HUMAN; LETTER; PARANOIA; PRIORITY JOURNAL; PSYCHOSIS; TOMOGRAPHY; DOSE RESPONSE; MIDDLE AGED; OBESITY; PSYCHOLOGICAL ASPECT; RISK FACTOR; TREATMENT WITHDRAWAL;

APPETITE DEPRESSANTS; BRIEF PSYCHIATRIC RATING SCALE; CYCLOBUTANES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MIDDLE AGED; OVERWEIGHT; PSYCHOSES, SUBSTANCE-INDUCED; RISK FACTORS; WITHHOLDING TREATMENT;

EID: 39649115238     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31815ac4c0     Document Type: Letter

References (19)

1. Luque CA, Rey JA. Sibutramine: a serotoninnorepinephrine reuptake-inhibitor for treatment of obesity. Ann Pharmacother [online]. 1999;33:968-978. Available at: http://www.theannals.com. Accessed February 25, 2005.
2. Behar R. Anorexígenos: indicaciones e interacciones. Rev Chil Neuropsiquiatr [online]. 2002;40(2):21-36. Available at: http://www.scielo.cl. Accessed February 25, 2005.
3. Luque CA, Rey JA. The discovery and status of sibutramine as anti-obesity drug. Eur J Pharmacol. 2002;440:119-128.
4. Balcioglu A, Wurtman RJ. Sibutramine, a serotonin uptake inhibitor, increases dopamine concentrations in rat striatal and hypothalamic extracellular fluid. Neuropharmacology. 2000;39:2353-2359.
5. Ukai K, Nakagawa T, Ohyama T, et al. Sibutramine induces potential-dependent exocytotic release but not carrier-mediated release of dopamine and 5-hydroxy tryptamine. Eur J Pharmacol. 2004;484:209-215.
6. Binkley K, Knowles SR. Sibutramine and panic attacks. Am J Psychiatry. 2002;159:1793-1794.
7. de Araújo Carlini EL, Nappo SA. The pharmacovigilance of psychoactive medications in Brazil. Rev Bras Psiquiatr. 2003;25(4):200-205.
8. Taflinki T, Chojnacka J. Sibutramine-associated psychotic episode. Am J Psychiatry. 2000;157:2057-2058.
9. McLaren KD, Marangell LB. Special considerations in the treatment of patients with bipolar disorder and medical comorbidities. Ann Gen Hosp Psychiatry. 2004;3:7.
10. Bushe CH, Haddad P, Peveler R, et al. The role of lifestyle interventions and weight management in schizophrenia. J Psychopharmacol. 2005;19(6):28-35.
11. Salazar LE. Tratamiento farmacológico de la obesidad Sibutramina. Available at: http://www.nutrinfo.com.ar/pagina/info/sibutram.html. Accessed August 4, 2005.
12. Wolf C, Tanner M. Obesity. West J Med. 2002;176:23-28.
13. Finer N. Sibutramine: its mode of action and efficacy. Int J Obes. 2002;26(4):S29-S33.
14. Arfken CL, Cicero TJ. Postmarketing surveillance for drug abuse. Drug Alcohol Depend. 2003;70:S97-S107.
15. Saiz Ruiz J, Saiz González D, Fructuoso PA. Potencial abuso de sibutramina. Med Clin (Barc). 2003;120(16):638-639.
16. Stahl SM. Psychopharmacology of reward and drugs of abuse. In: Essential Psychopharmacology. Neuroscientific Basis and Practical Applications. 2nd ed. New York: Cambridge University Press; 2000.
17. López Ibor Aliño JJ, Valdés Miyar M. Esquizofrenia y otros trastornos psicóticos. In: DSM-IV-TR. Manual diagnóstico y estadítico de los trastornos mentales. Masson, Barcelona; 2002.
18. Sierra M, Berrios GE. The phenomenological stability of depersonalization: comparing the old with the new. J Nerv Ment Dis. 2001;189:629-636.
19. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.